New indications for antidepressants

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 11, 2000, Pages 9-17

  Schatzberg, A F ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALCOHOLISM; ANXIETY NEUROSIS; BORDERLINE STATE; BULIMIA; CHRONIC FATIGUE SYNDROME; DEPRESSION; DRUG APPROVAL; DRUG MECHANISM; DYSPHORIA; FOOD AND DRUG ADMINISTRATION; HUMAN; OBESITY; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; SOCIAL PHOBIA; TREATMENT INDICATION;

ALCOHOLISM; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COMORBIDITY; DEPRESSIVE DISORDER; EATING DISORDERS; FATIGUE SYNDROME, CHRONIC; HUMANS; MENTAL DISORDERS; PREMENSTRUAL SYNDROME; STRESS DISORDERS, POST-TRAUMATIC;

EID: 0033855566     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder
2. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
3. Paroxetine efficacy in the treatment of generalized anxiety disorder
4. Mirtazapine in major depression with comorbid generalized anxiety disorder
5. An open trial of nefazodone in adult patients with generalized anxiety disorder
6. Obsessive-compulsive and spectrum disorders: Overview and quality of life issues
7. SSRIs and SNRIs: Broad spectrum of efficacy beyond major depression
8. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study
9. Pharmacologic treatment of obsessive-compulsive disorder: Comparative studies
10. An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive compulsive disorder
11. Setting diagnostic thresholds for social phobia: Considerations from a community survey of social anxiety
12. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
13. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study
14. Psychopharmacological treatment of social phobia: A double blind placebo controlled study with fluvoxamine
15. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
16. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders
17. Venlafaxine in social phobia
18. Nefazodone for social phobia: A clinical case series
19. Nefazodone in social phobia
20. Paroxetine in the treatment of panic disorder: A randomised, double-blind, placebo-controlled study
21. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
22. Sertraline in the treatment of panic disorder: A double-blind multicenter trial
23. An open trial of fluoxetine in the treatment of panic attacks
24. Serotonin function in panic disorder: A double-blind placebo controlled study with fluvoxamine and ritanserin
25. Current concepts in the treatment of panic disorder
26. Low-dose venlafaxine treatment in panic disorder
27. An open-label trial of nefazodone in high comorbidity panic disorder
28. Nefazodone and the treatment of panic [letter]
29. Management of posttraumatic stress disorder: Diagnostic and therapeutic issues
30. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder
31. Sertraline in the treatment of rape victims with posttraumatic stress disorder
32. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial
33. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder
34. Fluoxetine in posttraumatic stress disorder
35. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder
36. Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder
37. A pilot study of mirtazapine in post-traumatic stress disorder
38. Nefazodone in post-traumatic stress disorder: Results from six open-label trials
39. Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study
40. Fluoxetine treatment of severe premenstrual syndrome
41. Fluoxetine in the treatment of premenstrual dysphoria
42. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome
43. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: A randomized controlled trial
44. Fluvoxamine for premenstrual dysphoric disorder: A pilot study
45. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial
46. Long-term fluoxetine treatment of late luteal phase dysphoric disorder
47. Open trial of fluoxetine therapy for premenstrual syndrome
48. Nefazodone in the treatment of premenstrual syndrome: A preliminary study
49. Fluoxetine in borderline personality disorder
50. Fluoxetine trial in borderline personality disorder
51. Fluoxetine in the treatment of borderline and schizotypal personality disorders
52. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder
53. Venlafaxine in the treatment of borderline personality disorder
54. The use of selective serotonin reuptake inhibitors in eating disorders
55. Medication and psychotherapy in the treatment of bulimia nervosa
56. Long-term fluoxetine treatment of bulimia nervosa
57. Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating-specific psychopathology
58. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters
59. Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity
60. Fluoxetine: A randomized clinical trial in the treatment of obesity
61. Sertraline and relapse prevention training following treatment by very-low-calorie diet: A controlled clinical trial
62. Bupropion sustained release and smoking cessation
63. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
64. Mood, major depression, and fluoxetine response in cigarette smokers
65. Antidepressant pharmacotherapy helps some cigarette smokers more than others
66. Recommended drug treatment strategies for the alcoholic patient
67. Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial
68. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics
69. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine: Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder
70. Treatment of chronic fatigue syndrome with nefazodone
71. Nefazodone for patients with chronic fatigue syndrome